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Abstract
Objective: To evaluate epidemiological features of post vaccine acute disseminated encephalomyelitis (ADEM) by
considering data from different pharmacovigilance surveillance systems.
Methods: The Vaccine Adverse Event Reporting System (VAERS) database and the EudraVigilance post-
authorisation module (EVPM) were searched to identify post vaccine ADEM cases. Epidemiological features
including sex and related vaccines were analysed.
Results: We retrieved 205 and 236 ADEM cases from the EVPM and VAERS databases, respectively, of which 404
were considered for epidemiological analysis following verification and causality assessment. Half of the patients had
less than 18 years and with a slight male predominance. The time interval from vaccination to ADEM onset was 2-30
days in 61% of the cases. Vaccine against seasonal flu and human papilloma virus vaccine were those most
frequently associated with ADEM, accounting for almost 30% of the total cases. Mean number of reports per year
between 2005 and 2012 in VAERS database was 40±21.7, decreasing after 2010 mainly because of a reduction of
reports associated with human papilloma virus and Diphtheria, Pertussis, Tetanus, Polio and Haemophilus Influentiae
type B vaccines.
Conclusions: This study has a high epidemiological power as it is based on information on adverse events having
occurred in over one billion people. It suffers from lack of rigorous case verification due to the weakness intrinsic to
the surveillance databases used. At variance with previous reports on a prevalence of ADEM in childhood we
demonstrate that it may occur at any age when post vaccination. This study also shows that the diminishing trend in
post vaccine ADEM reporting related to Diphtheria, Pertussis, Tetanus, Polio and Haemophilus Influentiae type B and
human papilloma virus vaccine groups is most likely due to a decline in vaccine coverage indicative of a reduced
attention to this adverse drug reaction.
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Introduction
Acute disseminated encephalomyelitis (ADEM) is an immune
mediated inflammatory disorder of the central nervous system
(CNS) that commonly occurs within one month from antigenic
challenge [1]. Despite the majority of ADEM cases being
attributed to a post-infectious aetiology, other causes were
reported [2]. Post vaccine aetiology was described for 5% of all
ADEM cases [2] and several vaccines have been described to
be related to this condition [2,3]. The incidence of ADEM onset
ranges from 1/106 to 1/105 and may change between different
vaccine formulations [3]. Epidemiological data about this
adverse event are still missing; this may be due to the rarity of
post vaccine ADEM.
A possibility to tackle this issue is to rely on information from
pharmacovigilance (PV) databases. Several PV programmes
have aimed at identifying the onset of adverse reactions to
drugs and vaccines. These programmes are particularly
valuable as they collect spontaneous reports on large
populations.
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One of the biggest national and international databases is
the Vaccine Adverse Event Reporting System (VAERS).
VAERS collects approximately 28,000 adverse drug reactions
(ADRs) following vaccination per year [4]. Despite its known
limitations, this passive system allows identification of rare and
severe adverse events following vaccination [5].
Another international database, the EudraVigilance post-
authorisation module (EVPM) is a database of all reports of
suspected serious adverse reactions from the European Union
(EU) [6]. As a whole these databases retrieve ADR from more
than one billion people.
The goal of this study was to evaluate epidemiological




For this surveillance, we considered both the EVPM and the
VAERS database for national (domestic) and international
(non-domestic) ADRs. From VAERS we were able to extract
data regarding age, gender, onset interval, clinical outcome as
well as related vaccine and year of vaccination. For each
reports case description was extracted and considered for case
evaluation.
Data from the EVPM database were instead extracted
though manual search among ADR reports organised by
substances. For each vaccine, we extracted data regarding
age, gender and clinical outcome. Onset interval and year of
vaccination were not available.
Case evaluation
Cases retrieved from the VAERS database were reviewed
considering the signs, symptoms and diagnosis within each
identified report. A case was considered verified if: (i) the report
clearly stated the diagnosis of ADEM or described signs and
symptoms consistent with ADEM diagnosis [1]; (ii) the patient
was not diagnosed with Multiple Sclerosis; (iii) the report did
not describe any previous infective episode. Unverified cases
were excluded from further analyses.
Causality evaluation
Causality evaluation of VAERS cases was performed using
the WHO criteria [7] in order to minimise the known limits of
these databases, i.e. misreporting and low data quality. Almost
30% of ADEM onset do not relate to a clinically evident
infection or vaccination [1]. The classification term “very likely/
certain” was therefore not used in this classification since it
requires that post vaccination ADEM “could not be explained
by current disease”. Cases defined as “unrelated” or “unknown”
were excluded from further analyses.
We did not carry out causality evaluation of EVPM cases as
this information is already provided as such by the database
itself.
Two different referees with comparable PV expertise
evaluated each report and supplementary materials in order to
classify the causal association between vaccination and ADEM
using WHO criteria. The referees completed their causality
assessment independently and they resolved any discordance
via internal discussion.
Epidemiological analysis
A descriptive statistical analysis was performed to
summarise the main characteristics of the cases retrieved from
the VAERS and EVPM databases. Due to the differences
among these databases, we analysed and present data distinct
by database.
For each database the distribution of the related vaccines
was analysed and described.
Frequency of ADEM was assessed by considering VAERS
data from the time frame between 2005 and 2012. Data from
year 2013 were not included in the analysis to prevent any
possible bias. A descriptive analysis of related vaccines was
performed considering the overall and per year frequencies.
In order to evaluate the causes of variability in related
vaccines within the per year frequency of ADEM cases, data
regarding vaccine coverage in the US [8] with relative cases
was used as a comparison.
All statistical analyses were performed with the MedCalc v.
12.1.4 software (BVBA).
Results
Case selection and causality assessment
From the VAERS database we retrieved 236 cases of ADEM
following vaccination.
Causality assessment, performed using the WHO criteria,
showed a probable relationship between vaccine and ADEM in
38% of the cases, while only 9% (20 cases) were unrelated
(table 1). 15% was found to be “unrelated”, “unclassifiable” or
excluded because not verified during initial assessment while
85% of the cases was classified as ”probable”, “possible” or
“unlikely”. These 199 cases were considered for the
epidemiological analysis. Likewise, we retrieved 205 cases
from the EVPM database that were classified as related to
vaccination and thus used in the epidemiological analysis.
Patients’ characteristics
Among the VAERS reports considered in our analysis, 93%
included information on patients’ age and 97% on patients’
gender (table 1). Almost half of the patients had less than 18
years, while only 6% were over 65. We observed a similar age
distribution among the EVPM reports, with seven cases (3%)
older than 65 years and 99 cases (48%) younger than 18 years
(table 1).
Among the VAERS reports there was a slight predominance
of females (table 1), as 12% of the reports was related to the
sex specific vaccination against human papilloma virus (HPV).
Consistent with the VAERS data, reports from the EVPM
database also showed a predominance of female patients
mainly due to sex specific vaccination (table 1). Correcting for
this factor revealed a slight male predominance, in both
databases with a female/male ratio of 0.66 and 0.91 for the
VAERS and EVPM databases, respectively.
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All reports from the VAERS database recorded the time
elapsed between vaccination and ADEM symptoms onset
Table 1. Demographic data from surveillance databases.
Characteristic VAERS (%) EVPM (%)
Age    
 0-17 years 99 (48%) 94(48%)
 18-64 79 (40%) 92 (45%)
 65+ years 12 (6%) 7 (3%)
 Unknown/not reported 14 (7%) 7 (3%)
Sex    
 Male 93 (47%) 80 (39%)
 Female 101 (51%) 123 (60%)
 Unknown/not reported 5 (3%) 2 (1%)
Interval from vaccination to ADEM onset (days)   
 0-2 days 41 (21%)  
 2-30 days 121 (61%)  
 More than 30 days 37 (19%)  
Causality assessment   
 Probable 90 (38%)  
 Possible 77 (33%)  
 Unlikely 32 (14%)  
 Unrelated, unknown, unverified 37 (15%)  
doi: 10.1371/journal.pone.0077766.t001
(table 1). The time interval ranged between 2-30 days from
vaccination in 61% of the cases, while 37 patients (19%)
developed ADEM after one month. Such information is not
available on the EVPM database.
Related vaccines
Vaccination against seasonal flu (FLU) and HPV (HPV2&4)
were those most frequently associated with ADEM
development in both the VAERS and EVPM databases,
accounting together for almost 35% of the overall reports
(Figure 1).
The proportion of ADEM cases following the ten most
frequently reported vaccine was 76% in the VAERS database
and 97% in the EVPM database (Figure 1).
By grouping together vaccinations against Diphtheria,
Pertussis, Tetanus, Polio and Haemophilus Influentiae type B
(DTaP+IPV+HiB), we found that this was the vaccine group
most frequently associated with ADEM development in the
VAERS database (21%). This vaccine group accounted instead
for less than 15% of the ADEM cases in the EVPM database.
Figure 2 shows the frequency of post vaccine ADEM
assessed between 2005 and 2012 in the VAERS database; the
mean number of reports per year was 40±21.7, with the highest
number of reports in 2009. Since 2010, the frequency of ADEM
reporting per year decreased mainly due to a reduction of
reports associated with HPV2&4 and DTaP+IPV+HiB vaccines
Figure 1.  Most commonly related vaccine in the VAERS and EVPM databases.  The histograms show the relative distribution
of the ten commonest vaccine related to ADEM cases in the VAERS and EVPM databases. HPV (2&4): human papilloma virus
vaccine, bivalent and quadrivalent; FLU: seasonal flu vaccine; FLU H1N1: H1N1 vaccine; MMR: measles, mumps, and rubella
vaccine; PCV: pneumococcal conjugate vaccine; MNQ meningococcal vaccine; DTAP: Diphtheria, Pertussis, Tetanus; HEP B:
Hepatises B vaccine; HEP A+B: Hepatitis A and B vaccine; HEXA: hexavalent vaccines; VARCEL: varicella vaccine; IPV:
inactivated poliovirus vaccine; TDAP: vaccine against tetanus, diphtheria, and pertussis in adolescents.
doi: 10.1371/journal.pone.0077766.g001
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(Figure 2). The frequency of ADEM reports related to flu
vaccination was instead constant in this period.
We observed a discrepancy between the decreasing
frequencies of ADEM reports per year following HPV2&4 and
DTaP+IPV+HiB vaccines and vaccine coverage in the same
time-span which was constant (DTaP+IPV+HiB) or increased
(HPV2&4). This analysis was not done on the EVPM database
as it does not report the year of ADEM onset.
By considering vaccines most commonly involved in a
specific age group from the VAERS database, we observed
that vaccines against measles, mumps, and rubella (MMR) and
FLU were those most commonly involved in the 0-5 years age
group (13%), followed by pneumococcal conjugate vaccine
(PCV) (11%) and DTaP (9%). Vaccines against HPV(2&4) and
meningococcus (MNQ) represented the most frequently
suspected causes of ADEM in the age group 6-17 years with
26% and 21% of the cases, respectively. Seasonal flu vaccine
was the most frequently suspected cause of ADEM after 18
years, representing 32% of the total cases (Figure 3). Data
from the EVPM database were consistent with those of the
VAERS database (Figure 4).
Discussion
In this study we report the first characterisation of
epidemiologic data regarding ADEM following vaccination
considering a large number of reports arising from the two
largest PV safety databases, covering more than 1 billion
persons in the US and EU.
Previous reports on ADEM indicated that this condition is
commoner in children than in adults and is characterised by a
mean age of onset ranging from 5 to 8 years [1]. By contrast,
our study clearly shows that ADEM following vaccination
occurred in patients older than 18 years in almost 40% of the
cases. This suggest that ADEM, at least when post vaccine, is
not restricted to a specific age and that previously reported
age-related associations are linked to a specific setting in
which the observations were made [1,2].
Consistent with this hypothesis we observed a shift in
suspected vaccines in different age groups: vaccine against
PCV, DTaP and MMR represented the most frequently
suspected group of ADEM occurring between 0 and 5 years
while ADEM following vaccination against HPV were the most
frequently reported in the age group 6-17 years. After 18 years,
FLU represented the vaccination most frequently associated
with ADEM. A male predominance for ADEM had been
described in two paediatric cohorts [9,10], though globally no
gender predominance was reported. Consistent with these two
studies and after correction for the presence of female patients
with ADEM following HPV2&4 vaccine, we observed a male
predominance in post vaccination ADEM.
Time between antigenic challenge and ADEM onset is
generally described as ranging between 2 days and 4 weeks
[1] even though this varies among different studies and almost
25% of the patients did not report any antecedent infection or
Figure 2.  ADEM cases from the VAERS database.  The graph shows the number of cases (black line) and the frequency of
specific vaccine groups per years. DTaP+IPV+HiB: Vaccine against Diphtheria, Pertussis, Tetanus, Polio and Haemophilus
Influentiae type B; FLU: seasonal flu vaccine; FLU H1N1: H1N1 vaccine; HPV (2&4): human papilloma virus vaccine, bivalent and
quadrivalent.
doi: 10.1371/journal.pone.0077766.g002
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vaccination within a few weeks before ADEM onset [1].
According to these data, our study shows that ADEM
developed after 30 days from vaccination in only 19% of cases.
From the information available to us we cannot determine
whether this delayed onset underlies a delayed onset of this
ADR or is due to unreported or subclinical/undetected infection
having occurred in the period between vaccination and the
onset of ADEM.
The highest frequency of ADEM observed following FLU and
HPV(2&4) does not automatically imply that these vaccines are
associated with a higher risk of ADEM development.
Vaccination against HPV was introduced only recently for small
target populations and this may increase awareness of the
physicians to subsequent ADRs resulting in a high number of
reported cases. On the contrary, vaccination against FLU is
administered to a larger number of subjects thus high numbers
of reports may be the consequence of the large distribution of
the vaccine despite a lower incidence of ADEM following it
[11,12]. Other factors, such as the limited interest into an
already know ADR following FLU vaccine, could also affect
reporting rate, resulting in a lower incidence.
It was previously stated that the vaccinations against MMR
are those most commonly associated with ADEM [13]. By
contrast, our data, obtained from a large database analysis,
indicate that this is not the case as only a small amount of total
ADEM cases was related to this group of vaccines with respect
of the large number of doses distributed and high vaccine
coverage in US and EU [14].
Since these data arise from passive surveillances systems,
we cannot draw conclusions on the possible differences in the
risk of ADEM following a specific vaccine.
This study shows a diminishing trend in post vaccine ADEM
reporting related to the DTaP+IPV+HiB vaccine group, which
was frequently reported between 2007 and 2009 but less
represented in the following years. Yet the coverage of this
vaccine group among the US population has remained fairly
constant [8]. We found a similar trend also for the vaccination
against HPV with at least one dose. This vaccination increased
from 25% in 2007 to 51% in 2011 [8], yet the frequency of
reports due to HPV vaccine decreased. Such discrepancies in
vaccination coverage vs. ADEM reports may indicate a lower
interest on ADRs, which is a known cause of under-reporting
[5].
This study has some limitations as it is a retrospective study
based on data retrieved from passive PV surveillance systems,
which may suffer from under-reporting and differential reporting
[15]. An important issue of these epidemiological studies is the
lack of a rigorous verification of the cases and the different way
of data verification in the two databases.
Since the VAERS staff follows up on all serious ADR to
obtain additional medical records, many of the ADEM reports
are analysed further and the risk of misdiagnosis thus reduced.
Figure 3.  Most frequently reported vaccines in the VAERS database divided by age groups.  The histogram shows the
relative distribution of the three most common vaccine related to ADEM cases in the VAERS database by considering different age
groups. MMR: measles, mumps, and rubella vaccine; PCV: pneumococcal conjugate vaccine; DTAP: Diphtheria, Pertussis, Tetanus
vaccine; HPV (2&4): human papilloma virus vaccine, bivalent and quadrivalent; MNQ meningococcal vaccine; TDAP: vaccine
against tetanus, diphtheria, and pertussis in adolescents; FLU: seasonal flu vaccine; TYP: Typhoid Vaccine.
doi: 10.1371/journal.pone.0077766.g003
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Reports to EVPM database arise from medical doctors or
pharmacists who directly interact with the patient. With this
system, the number of unchecked reports is very low and the
quality of reports should be higher.
Despite these mechanisms of verification and our performing
case verification, the risk of misdiagnosis that could possibly
lead to the introduction of false positive and the exclusion of
false negative cases in this analysis has to be highlighted.
Another possible issue that should be highlighted is the risk
of case overlaps between the EVPM and VAERS databases
limited to the VAERS non domestic cases since we cannot
evaluate the geographical source of each of them.
Since the EVPM and VAERS databases do not provide
information on patient race or ethnic group, we were unable to
analyse such factors. Further studies based on different
databases may provide insight in this direction.
Despite these limitations, we provide the first epidemiological
study analysing the onset of post vaccine ADEM with special
regards to age of onset, sex and related vaccines. Our findings
do not support previous evidence in the literature on an
increased frequency of ADEM following vaccination in
childhood and highlight the role of the different vaccines during
lifetime. Moreover, we observed a shift in the ADEM-related
vaccines that may be explained by a change in the reporting
pattern, rather than by a change in ADEM epidemiology.
Higher attention towards this specific ADR would be
important in order to define better the incidence of post vaccine
ADEM.
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